BeOne Medicines (ONC) Assets (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Assets of $8.6 billion for Q1 2026, up 46.43% year-over-year from $5.8 billion in Q1 2025, and up 4.46% quarter-over-quarter from $8.2 billion in Q4 2025.
BeOne Medicines (ONC) Assets (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Assets for 12 consecutive years, with $8.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 46.43% year-over-year to $8.6 billion; the TTM figure through Mar 2026 stood at $8.6 billion (up 46.43% YoY), while the FY2025 annual figure was $8.2 billion, up 38.3% from the prior year.
- Assets climbed to $8.6 billion in Q1 2026 per ONC's latest filing, from $8.2 billion in the prior quarter.
- Across five years, Assets topped out at $8.6 billion in Q1 2026 and bottomed at $5.5 billion in Q4 2022.
- Historically, Assets has averaged $6.5 billion across 5 years, with a median of $5.9 billion in 2024.
- Annual changes were most pronounced in 2022 — Assets slumped 35.78% — and 2026, when it jumped 46.43%.
- BeOne Medicines' Assets stood at $5.5 billion in 2022, then increased by 5.91% to $5.8 billion in 2023, then rose by 1.99% to $5.9 billion in 2024, then soared by 38.3% to $8.2 billion in 2025, then rose by 4.46% to $8.6 billion in 2026.
- Business Quant data shows ONC's Assets at $8.6 billion in Q1 2026, $8.2 billion in Q4 2025, and $7.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.18 Bn |
| Mar 31, 2026 | 8.55 Bn |
| Dec 31, 2025 | 8.19 Bn |
| Sep 30, 2025 | 7.63 Bn |
| Jun 30, 2025 | 6.30 Bn |
| Mar 31, 2025 | 5.84 Bn |
| Dec 31, 2024 | 5.92 Bn |
| Sep 30, 2024 | 5.83 Bn |
| Jun 30, 2024 | 5.71 Bn |
| Mar 31, 2024 | 5.67 Bn |
| Dec 31, 2023 | 5.81 Bn |
| Sep 30, 2023 | 5.52 Bn |
| Jun 30, 2023 | 5.73 Bn |
| Mar 31, 2023 | 5.96 Bn |
| Dec 31, 2022 | 5.48 Bn |
| Sep 30, 2022 | 6.73 Bn |
| Jun 30, 2022 | 7.38 Bn |
| Mar 31, 2022 | 8.02 Bn |
| Dec 31, 2021 | 8.54 Bn |
| Sep 30, 2021 | 5.29 Bn |